Nearly 20% of U.S. children and adolescents have obesity. For decades, the treatment options were limited to lifestyle interventions that, while important, produce modest results in severe cases. GLP-1 medications are changing that equation—and the data in adolescents is remarkably strong.
FDA-Approved Uses in Adolescents
As of 2026, several GLP-1 medications have received FDA approval for use in adolescents (typically defined as ages 12 and older):
- Wegovy (semaglutide 2.4mg): Approved for chronic weight management in patients aged 12+ with obesity (BMI at or above the 95th percentile for age and sex)
- Saxenda (liraglutide 3.0mg): Approved for patients aged 12+ with obesity
- Zepbound (tirzepatide): Pediatric trials ongoing; pediatric approval expanding
The STEP TEENS Trial
The landmark trial for adolescent GLP-1 use was STEP TEENS, which tested semaglutide 2.4mg weekly in adolescents aged 12–17 with obesity.
STEP TEENS Results
- • 16.1% reduction in BMI with semaglutide vs. 0.6% with placebo at 68 weeks
- • 73% of participants achieved at least 5% weight loss
- • 45% achieved at least 10% weight loss
- • Significant improvements in cardiometabolic risk factors
- • Safety profile consistent with adult trials
These results were actually stronger than what was seen in adult trials—adolescents responded more robustly to the same dose of semaglutide. Researchers attribute this partly to the higher metabolic plasticity of younger patients.
Why This Matters: The Case for Early Intervention
Adolescent obesity isn’t a cosmetic concern. It’s a medical condition with serious long-term consequences:
- Type 2 diabetes in children has increased 95% in the past two decades
- Fatty liver disease (MASH) is now the most common liver disease in children
- Cardiovascular risk factors (hypertension, high cholesterol) are increasingly diagnosed in teenagers
- 80% of adolescents with obesity will continue to have obesity as adults
- Mental health impact: Obesity in adolescence is associated with higher rates of depression, anxiety, and social isolation
Early intervention can break these cycles before they become entrenched adult diseases. This is the core argument for making GLP-1 medications available to adolescents who meet clinical criteria.
Safety in Adolescents
What the Trials Showed
The safety profile in adolescents was consistent with adult data. The most common side effects were GI-related: nausea (up to 36%), vomiting, diarrhea, and abdominal pain. Most side effects were mild to moderate and occurred during dose titration.
Growth and Development Concerns
This is the question every parent asks first. The available data is reassuring but limited:
- STEP TEENS did not show adverse effects on linear growth (height) during the 68-week study period
- Puberty progression was not significantly affected
- Bone density data is still being collected but no red flags have emerged
- Longer-term studies (2+ years) are ongoing to fully characterize growth effects
What We Don’t Know Yet
GLP-1 medications in adolescents have only been studied for periods of about 1–2 years. We do not yet have data on how multi-year use during adolescence affects long-term growth, bone mineral density, fertility, or metabolic function. Families should weigh the known risks of untreated adolescent obesity against the unknowns of long-term medication use.
Who Qualifies
GLP-1 medications for adolescents are not a first-line treatment. Clinical guidelines recommend a stepwise approach:
- Step 1: Intensive lifestyle interventions (nutrition counseling, physical activity programs, behavioral therapy) for at least 3–6 months
- Step 2: If lifestyle interventions are insufficient and BMI remains at or above the 95th percentile, pharmacotherapy (including GLP-1 medications) can be considered
- Step 3: For severe obesity (BMI ≥ 120% of the 95th percentile), guidelines allow earlier medication consideration alongside lifestyle changes
The prescribing provider should be experienced in pediatric obesity management, and the adolescent should receive ongoing monitoring including regular lab work, growth tracking, and mental health screening.
Practical Considerations for Families
Cost and Access
Insurance coverage for pediatric GLP-1 use varies widely. Some plans cover Wegovy for adolescents; many don’t. Brand-name Wegovy costs $1,000+ per month without insurance. Compounded semaglutide is not FDA-approved for any age group, but some families explore it as a more affordable alternative under provider guidance.
The Whole-Family Approach
Medication works best when combined with family-wide changes. Research consistently shows that adolescent weight management outcomes improve when the entire household participates in healthier eating, more physical activity, and reduced screen time. The medication reduces biological hunger; the family environment shapes the habits.
Mental Health Monitoring
Adolescence is already a period of intense psychological change. Adding a weight loss medication—and the body changes that come with it—requires careful attention to mental health. Providers should screen for depression, anxiety, disordered eating, and body image concerns at every follow-up visit.
The Bottom Line
GLP-1 medications represent a genuine breakthrough for adolescents with severe obesity. The clinical data shows robust weight loss, improved cardiometabolic health, and an acceptable safety profile. But they’re not a shortcut—they work best as part of a comprehensive approach that includes lifestyle changes, family involvement, and close medical monitoring. If your child is struggling with severe obesity, talk to a pediatric endocrinologist or obesity specialist about whether GLP-1 therapy is appropriate.